Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

(UPDATE) EU Standards: Potential Hiatus As Priorities, Deadlines And Timeframes Take Shape

Executive Summary

The European Commission’s long overdue MDR/IVDR standards request document – still a draft – gives the European standards bodies just over a week from today to respond. But CEN/Cenelec says it cannot reply yet. So what is the problem?

You may also be interested in...



Commission Invites European Standards Bodies To Accept MDR/IVDR Standardization Request

The European Commission has at last officially requested that CEN and CENELEC develop and update urgently needed standards to support the MDR and IVDR. The pressure is now on the national European standards bodies to press on with the necessary work.

European Commission's Device Standardization Request Imminent

After a failed attempt last year, the formal standardization request from the European Commission to the European standards bodies will shortly kickstart essential standards work to support compliance with the Medical Device Regulation.

EU Regulatory Roundup, September 2023: Dismantling Regulatory Barriers To Medtech Innovation

The call for more to be done about the EU’s regulatory hurdles to innovation, as well as for improvements to governance, has now grown to a crescendo. While the EU looks at how best to move forward, innovation in the UK is benefiting from greater regulatory freedoms.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel